Biohaven Stock Catapults On A Surprise FDA Move Why It Might Not Be Done Running
Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug, troriluzole.
ETH-5.43%
BTC-4.13%
SOL-4.87%
XRP-6.32%
USDC+0.03%
DOGE-6.18%
SUI-7.51%
HYPE-5.68%ETH-5.43%BTC-4.13%SOL-4.87%XRP-6.32%USDC+0.03%DOGE-6.18%SUI-7.51%HYPE-5.68%ETH-5.43%BTC-4.13%SOL-4.87%XRP-6.32%USDC+0.03%DOGE-6.18%SUI-7.51%HYPE-5.68%ETH-5.43%BTC-4.13%SOL-4.87%XRP-6.32%USDC+0.03%DOGE-6.18%SUI-7.51%HYPE-5.68%
